ForPatients
by Roche

Healthy Volunteers

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02711423 2015-005132-17 BP30042

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This two-part study is designed to assess the safety, tolerability, and PK of gantenerumab in healthy volunteers. Part I (dose escalation) will randomly assign participants to receive a single blinded SC dose of gantenerumab or placebo. Part II (PK extension) will randomly assign participants to receive a single open-label SC dose of ganenerumab at different dose levels according to safety assessments from Part I.

Hoffmann-La Roche	Phase 1
Sponsor	Phase

NCT02711423 2015-005132-17 BP30042
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Male	>= 18 Years & <= 45 Years	Accepts Healthy Volunteers